Last reviewed · How we verify

NCT05296655

Kazakh Version of Reflux Symptom Index

Completed Last updated 23 May 2022
What this trial tests

trial testing Reflux Symptom Index Inventory (diagnostic survey) in Laryngopharyngeal Reflux Symptoms in 248 participants. Completed in 16 February 2022.

Timeline
1 March 2020
Primary endpoint
15 February 2022
16 February 2022

Quick facts

Lead sponsorKazakh Medical University of Continuing Education
StatusCompleted
Study typeOBSERVATIONAL
Enrollment248
Start date1 March 2020
Primary completion15 February 2022
Estimated completion16 February 2022
Sites2 locations across Kazakhstan

Drugs / interventions tested

Conditions studied

Sponsor

Kazakh Medical University of Continuing Education

Who can join

Adults 18 to 74, any sex, with Laryngopharyngeal Reflux Symptoms or Laryngopharyngitis Chronic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Reflux symptoms index (RSI) were developed to identify a clinical index of suspicion for laryngopharyngeal reflux (LPR) in patients with ear, nose, and throat symptoms. RSI is an efficient diagnostic tool for LPR/ It is easy to use, even for those who know little about LPR. It does not require special equipment or examinations and is inexpensive. Thus, it can be considered highly efficient and cost-effective. The study will focus on translating and testing the RSI into Kazakh language and comparing its results in healthy people and people with laryngopharyngeal reflux.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Kazakh Medical University of Continuing Education trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05296655.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing